Hypomethylation of the IL17RC Promoter Associates with Age-Related Macular Degeneration  by Wei, Lai et al.
Cell Reports
ReportHypomethylation of the IL17RC Promoter
Associates with Age-Related Macular Degeneration
Lai Wei,1,2,3,* Baoying Liu,1 Jingsheng Tuo,1 Defen Shen,1 Ping Chen,1 Zhiyu Li,1 Xunxian Liu,3 Jia Ni,1 Pradeep Dagur,4
H. Nida Sen,1 Shayma Jawad,1 Diamond Ling,1 Stanley Park,1 Sagarika Chakrabarty,1 Catherine Meyerle,5 Elvira Agron,5
Frederick L. Ferris 3rd,5 Emily Y. Chew,5 J. Philip McCoy,4 Emily Blum,6 Peter J. Francis,6 Michael L. Klein,6
Robyn H. Guymer,7 Paul N. Baird,7 Chi-Chao Chan,1 and Robert B. Nussenblatt1,2,3,*
1Laboratory of Immunology, National Eye Institute
2Center for Human Immunology, Autoimmunity and Inflammation
3National Center for Complementary and Alternative Medicine
4Hematology Branch, National Heart Lung and Blood Institute
5Division of Epidemiology and Clinical Research, National Eye Institute
National Institutes of Health, Bethesda, MD 20892, USA
6Macular Degeneration Center and Leonard Christensen Eye Pathology Laboratory, Casey Eye Institute, Oregon Health & Science University,
Portland, OR 97239, USA
7Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria 3002, Australia
*Correspondence: lai.wei@nih.gov (L.W.), drbob@nei.nih.gov (R.B.N.)
http://dx.doi.org/10.1016/j.celrep.2012.10.013SUMMARY
Age-related macular degeneration (AMD) is the
leading cause of irreversible blindness in the elderly
population worldwide. Although recent studies
have demonstrated strong genetic associations
between AMD and SNPs in a number of genes, other
modes of regulation are also likely to play a role in the
etiology of this disease. We identified a significantly
decreased level of methylation on the IL17RC
promoter in AMD patients. Furthermore, we showed
that hypomethylation of the IL17RC promoter in AMD
patients led to an elevated expression of its protein
and messenger RNA in peripheral blood as well as
in the affected retina and choroid, suggesting that
the DNA methylation pattern and expression of
IL17RC may potentially serve as a biomarker for the
diagnosis of AMD and likely plays a role in disease
pathogenesis.INTRODUCTION
Age-related macular degeneration (AMD) is the most common
cause of irreversible central blindness in the older population
worldwide. It currently affects more than 1.75 million individuals
in the United States alone, and it has been estimated that this
number will increase to almost 3 million in 10 years (Friedman
et al., 2004). AMD leads to progressive loss of central vision
due to macular atrophy or choroidal neovascularization (CNV).
Currently, nomedical or surgical treatment is available for central
geographic atrophy (GA), the ‘‘dry’’ form of advanced AMD;
however, antivascular endothelial growth factor (anti-VEGF)
drugs such as ranibizumab (Lucentis) and bevacizumab (Avastin)Cell Rehave been used to treat CNV AMD, the ‘‘wet’’ form of advanced
AMD (Campa and Harding, 2010).
In the past two decades, genetic susceptibility factors for AMD
have been extensively studied and documented. DNA variants in
a growing list of genes have been identified as strong genetic
contributors to the etiology of AMD (Swaroop et al., 2009),
including complement factor H (CFH) gene, CFB, complement
2, complement 3 (C3), and complement factor I (CFI). In addition
to genes within the complement pathway, the ARMS2/HTRA1
region, apolipoprotein E (APOE), tissue inhibitor of metalloprotei-
nase 3 (TIMP3), cholesteryl ester transfer protein (CETP), ATP-
binding cassette subfamily A member 1 (ABCA1), and hepatic
lipase gene (LIPC) have also been associated with AMD (Tuo
et al., 2012). Although investigators have achieved considerable
success in deciphering the genetic risk factors associated with
the etiology of AMD in various studies, such studies have been
limited by the lack of direct functional links between genes and
the pathogenesis of the disease, as well as an inconsistency
among genetic studies (Peter and Seddon, 2010). In addition,
several major nongenetic risk factors for AMD, including aging,
smoking, diet, and inflammation (de Jong, 2006, Swaroop
et al., 2009, Baird et al., 2006), have been reported. However,
the mechanism by which these environmental factors affect
the retina during the pathogenesis of AMD is largely unknown.
Epigenetic regulation, which includes DNA methylation and
histone modifications, is the main mechanism by which gene
expression patterns can be altered depending on the environ-
mental stimulus, without a change in DNA sequence. In verte-
brates, DNA can be methylated by DNA methyltransferase,
and this modification occurs mostly in the context of CpG dinu-
cleotides. DNA methylation has a substantial influence on chro-
matin structure and mediates silencing of gene expression
(Bernstein et al., 2007). Recent studies have indicated that
dynamic regulation of DNA methylation plays an important role
in pluripotent stem cell differentiation and tumorigenesis (Fein-
berg, 2007). A number of therapeutic agents that modulateports 2, 1151–1158, November 29, 2012 ª2012 The Authors 1151
Figure 1. Fundus Photographs of Twins with Discordant AMD
Twins with AMD were named AMD 1, AMD 2, and AMD3; twins without AMD
were named Non-AMD 1, Non-AMD2, and Non-AMD 3, respectively.DNA methylation patterns have been tested in clinics for cancer
treatment (Cedar and Bergman, 2009).
Wewere interested in assessing whether methylation changes
could be identified through the analysis of twin pairs, because
such analyses provide a means of dissecting the genetic and
environmental components of disease. Although the majority of
identical twins are concordant for end-stage AMD, a small
minority present with a discordant phenotype. We recently iden-
tified twins and siblings who display such a discordant disease
phenotype for AMD. This argues that nongenetic factors also
play a potentially crucial role in the pathogenesis of AMD. Recent
studies of genome-wide DNA methylation and histone modifica-
tions in identical twins with discordant disease phenotypes
support the notion that environmentally driven epigenetic
changes contribute to the etiology of diseases such as systemic
lupus erythematosus andmultiple sclerosis (Javierre et al., 2010,
Baranzini et al., 2010, Kaminsky et al., 2009, Fraga et al., 2005).
In this study, we initially investigated genome-wide differences in
DNAmethylation patterns between twins (bothmonozygotic and
dizygotic) with discordant AMD, and further validated methyla-
tion changes identified at the IL17RC promoter in siblings with
discordant AMD as well as in an AMD case control cohort of
patients with either the dry or wet form of AMD. Furthermore,
we evaluated IL17RC expression in the eyes and blood of
AMD patients.
RESULTS
Difference in DNA Methylation Patterns between Twins
and Siblings with Discordant AMD
Three pairs of twins (one monozygotic and two dizygotic) with
phenotypically discordant AMD were identified from our twin
patient cohort at the Centre for Eye Research Australia (CERA).
Age and gender information regarding these subjects is provided
in Table S1. As shown in Figure 1, the fundus photographs of the1152 Cell Reports 2, 1151–1158, November 29, 2012 ª2012 The Autpatients (named non-AMD 1, non-AMD 2, and non-AMD 3,
respectively) show a normal-appearing retina and no evidence
of drusen in any of the eyes. In contrast, the photographs of their
monozygotic (AMD 1) and dizygotic (AMD 2 and AMD 3) twins
show evidence of macular hemorrhage that was secondary to
CNV (AMD 1), multiple large drusen (AMD 2), and GA (AMD 3).
Monozygotic and dizygotic twins have identical or very similar
genetic backgrounds; therefore, we hypothesized that the
phenotypic difference between the AMD twins could be due to
epigenetic diversity, in addition to the difference in genetic infor-
mation between twin pairs.
Although traditionally AMD has been considered a neurode-
generative disease, the recently reported association between
AMD and SNPs in genes involving the immune response, such
as CFH, CFB, CFI, C3, ARMS2/HTRA1, CX3CR1, and TIMP3,
argues that a dysregulated immune system may play an essen-
tial role during the onset and duration of AMD (Swaroop et al.,
2009). In addition, in a recent small, randomized study, we found
that immunotherapy positively altered the clinical course of late-
stage neovascular AMD (Nussenblatt et al., 2010). Therefore, we
next obtained genomic DNA from peripheral blood mononuclear
cells (PBMCs), which could reflect the status of the immune
system, to investigate the DNA methylome difference between
AMD twins. We subjected the DNA to DNA methylation microar-
ray (MeDIP-chip) analysis using the NimbleGen Human DNA
Methylation 2.1M Deluxe Promoter Array. A total of 231 genes
showed consistent differential methylation patterns on their
promoters between AMD twins and their non-AMD cotwins
(Table S2). Consistent with the speculation that AMD may be
an immunological disease, our gene ontology enrichment
analysis using Ingenuity Systems (http://www.ingenuity.com/)
identified ‘‘immunological disease’’ as one of the fivemost signif-
icantly enriched gene categories among the list of genes with
differential DNA methylation patterns between twins (Table S3).
However, we did not find consistent DNA methylation changes
in AMD patients on the promoters of CFH, HTRA1, ARMS2 (Fig-
ure S1A), CFB, CFI, C3, TIMP3, TLR3, and TLR4 (data not
shown).
In a recent study, we demonstrated elevated serum levels of
the Th17 cytokines interleukin (IL)-17A and IL-22 in AMDpatients
(Liu et al., 2011). Previous studies also indicated the induction of
IL-17A by complement C5a (Hashimoto et al., 2010, Lajoie et al.,
2010). Importantly, our microarray analysis identified IL22,
IL17A, and IL17F as the top three most differentially induced
genes by C5A in CD4+ T cells between non-AMD controls and
AMD patients (Figure S1B). Therefore, among our list of 231
genes with differential methylation patterns between twin pairs,
we first focused on molecules that contribute to Th17 immunity.
Intriguingly, as shown in Figure 2A, the MeDIP-chip data sug-
gested that methylated CpG sites were found only in the twins
without AMD, and not in their AMD cotwins, in the promoter
regions of IL17RC, which encodes the receptor for IL-17A and
IL-17F dimers, as well as CCL22, which is the chemokine that
mediates trafficking of activated T lymphocytes to inflammatory
sites. In contrast, we did not find consistent DNA methylation
pattern differences on the promoters of the Th17 or Th1 cyto-
kines themselves, including IL17A, IL17F, IL22, IL26, and IFNG
(Figure S1C).hors
Figure 2. Hypomethylated IL17RC Promoters in AMD Patients
(A) Genome browser view of DNA methylation peaks, identified by MeDIP-chip analysis, on the loci of IL17RC and CCL22.
(B) Promoter methylation levels of IL17RC and CCL22 in seven pairs of siblings with discordant AMD phenotype.
(C) Promoter methylation level of IL17RC in 96 non-AMD controls and 202 AMD patients.
(D) Methylation levels of IL17RC promoters and their distribution in CNV and GA patients.
(E) Summary of the frequency of IL-17RC+ monocytes in the peripheral blood of 14 non-AMD controls and 34 AMD patients (NEI patient cohort).
(F) Promoter methylation level of IL17RC in the NEI patient cohort of 14 non-AMD controls and 34 AMD patients.
(G) Promoter methylation level of IL17RC in CD14+IL-17RC and CD14+IL-17RC+ monocytes isolated from the peripheral blood of AMD patients. Data are
expressed as the means ± SE from three AMD patients.
See also Figures S1 and S2.To test whether a similar DNA methylation pattern could be
found in other AMD patients with more diverse genetic back-
grounds, we identified seven pairs of siblings from our patient
cohort at the Casey Eye Institute (CEI; Oregon Health & ScienceCell ReUniversity, Portland, OR) who had discordant AMD phenotypes
(for all sibling pairs, one of the two had large drusen >125 mg
in diameter in at least one eye, and the other had no drusen).
We next carried out Methyl-Profiler assays to detect theports 2, 1151–1158, November 29, 2012 ª2012 The Authors 1153
methylation status on the promoters of IL17RC and CCL22 (Fig-
ure 2B). Intriguingly, a significant differential methylation status
between siblings with discordant AMD was found on the
promoter of IL17RC (p = 0.003, Mann-Whitney test). A hypome-
thylated IL17RC promoter was found only in the DNA from the
siblings with AMD, similar to what was observed in the discor-
dant twins. We also noted that no difference in methylation
status was found on the promoters of CCL22 in the sibling pairs
from Oregon, which was different from the promoter methyla-
tion patterns found in the twin pairs from Australia. To rule out
the possibility that the methylation pattern difference in
CCL22 promoters between these two patient cohorts was
CpG-site dependent, we designed two more primer pairs that
specifically targeted two other CpG sites as indicated in Fig-
ure 2A (sites 1 and 2). Using PBMC DNA samples from 34
AMD patients and 14 non-AMD controls collected in our clinics
at the National Eye Institute (NEI, National Institutes of Health
[NIH]), we performed Methyl-Profiler assays on the CCL22
promoter targeting CpG sites 1 and 2. As shown in Figure S2A,
no difference in methylation status was found on these two CpG
sites. In addition to the IL17RC and CCL22 promoters, we per-
formed Methyl-Profiler assays on the promoters of IL17F, IFNG,
IL26, CFH, and HTRA1. Consistent with our MeDIP results, we
did not find a consistent difference in methylation status on
these promoters in our NEI collected patient cohorts (34 AMD
patients and 14 non-AMD controls; Figure S2B). Taken
together, these data suggest that a hypomethylated IL17RC
promoter is associated with AMD disease not only in twins
but also in siblings.
A Hypomethylated IL17RC Promoter Was Found in 202
AMD Patients but Not in 96 Non-AMD Controls
It is well known that microarray-based methylation detection
technologies such as MeDIP-chip are prone to low specificity
(Fazzari and Greally, 2010). In addition, the NimbleGen MeDIP-
chip analysis provides only binary and fragment-level measure-
ments of DNA methylation on gene promoters. The genetic simi-
larity within a twin pair and within sibling pairs could also lead to
bias. Therefore, to investigate the methylation status of IL17RC
promoters in patients and healthy controls who did not share
known genetic similarities, we collected genomic DNA from the
PBMCs of 202 AMD patients (95 CNV and 107 GA) as well as
96 healthy individuals without AMD (non-AMD) from our clinics
at the NEI and CEI. The average ages of the AMD patients and
non-AMD controls were 80.5 and 70.2 years, respectively (Table
S1, Case-Control Patient Cohort). In similarity to our findingswith
both twins and siblings, we found a hypomethylated IL17RC
promoter in AMD patients and a hypermethylated IL17RC
promoter in non-AMD controls (95% confidence interval [CI],
0.03–0.17; p = 3.1 3 108, multivariable logistic regression
adjusted for age and gender; Figure 2C; Table S4). Interestingly,
the methylation status of the IL17RC promoters did not differ
significantly between patients with wet AMD and those with
dry AMD (p = 0.41, multivariable logistic regression adjusted
for age and gender; Figure S2C). However, the distribution of
these promoters was not identical betweenCNV andGApatients
(Figure 2D). Collectively, these results show an association
between AMD and a hypomethylated IL17RC promoter.1154 Cell Reports 2, 1151–1158, November 29, 2012 ª2012 The AutElevated Expression of IL-17RC in the Peripheral Blood
of AMD Patients
DNA methylation is generally associated with gene silencing. To
test whether DNA hypomethylation found on the promoter of
IL17RC results in gene desilencing and hence increased expres-
sion in only AMD patients, we performed a fluorescence-acti-
vated cell sorting (FACS) analysis of whole-blood samples,
together with other cell-surface markers that identify peripheral
hematopoietic cell lineages as well as the isotype control for
IL-17RC staining. Intriguingly, in the NEI patient cohort with 14
non-AMD controls and 34 AMD patients, we found a significantly
elevated frequency of IL-17RC+CD14+ monocytes in the periph-
eral blood of the AMD patients (Figures 3E and S3A). We consis-
tently found hypomethylated IL17RC promoters in these AMD
patients (Figure 3F). Importantly, we found that the methylation
level of the IL17RC promoter was significantly lower in the
CD14+IL-17RC+ cells than in the CD14+IL-17RC cells (Fig-
ure 3G), indicating that the elevated IL-17RC expression was
the result of demethylation of its promoter. In addition, we found
an increased frequency of IL-17RC+ cells among other types of
cells, including CD3+CD4CD8 and CD8+ T cells (but not
CD4+ T cells), from AMD patients as compared with age-
matched non-AMD controls (Figure S3B). These data suggest
that hypomethylation of the IL17RC promoter results in an
elevated expression of the IL-17RC protein on selected cells in
the peripheral blood of AMD patients.
Induction of IL-17RC Expression by IL-17A and IL-17F
Previous studies demonstrated that IL-17RC mediates both
IL-17A and IL-17F signaling (Ho and Gaffen, 2010). However, it
is not clear which factors regulate the expression of IL17RC.
As shown in Figures 4A and 4B, we found that both IL-17A and
IL-17F, through activation of NF-kB (Figure 4C), induced the
expression of IL-17RC in THP1 cells (a human acute monocytic
leukemia cell line) as well as in primary CD14+ monocytes. Our
microarray analysis also indicated a great difference in
genome-wide gene expression profiles between IL-17RC+ and
IL-17RC THP1 cells (Figure 4D). Using semiquantitative real-
time PCR, we confirmed that IL-17RC+ THP1 cells expressed
higher levels of the chemokine receptors CXCR1, CXCR2,
CXCR4, and CXCR7 (Figure 4E). Similarly, we also found
elevated expression of CXCR1, CXCR2, and CXCR4, but not
CXCR7, in CD14+IL-17RC+ cells from AMD patients as
compared with CD14+IL-17RC cells (Figure 4F). Moreover,
we found that IL-17A induced the expression of CXCR2 and
CXCR4 (Figure 4G). Therefore, our results suggest that
IL-17RC can be induced by both IL-17A and IL-17F, and
IL-17RC+ monocytes highly express the chemokine receptors
CXCR2 and CXCR4.
Elevated Expression of IL17RC in the Eyes of AMD
Patients
Previous studies suggested the involvement of monocytes/
macrophages in AMD pathogenesis (Nussenblatt et al., 2009,
Cao et al., 2011). Chemokine receptors expressed on the
cell surface play a critical role in enabling monocytes to exit
the vasculature through endothelial cells in the choroid or
retina. Because we found that IL-17RC+ monocytes highlyhors
Figure 3. Induction of IL-17RC by IL-17A and IL-17F in Monocytes, and Characteristics of IL-17RC+ Monocytes
(A) FACS staining of IL-17RC induced by IL-17A and IL-17F in THP1 cells.
(B) FACS staining of IL-17RC induced by IL-17A and IL-17F in primary CD14+ monocytes. See also Figure S3.
(C) Relative activity of NF-kB measured by TransAM NF-kB p65 transcription factor ELISA kit.
(D) Scatter plot showing the genome-wide expression difference between sorted IL-17RC+ and IL-17RC THP1 cells.
(E) Relative expression of CXCR1, CXCR2, CXCR4, and CXCR7 mRNA in sorted IL17RC+ and IL17RC THP1 cells.
(F) Relative expression of CXCR1, CXCR2, CXCR4, and CXCR7mRNA in sorted IL17RC+CD14+ and IL17RCCD14+ monocytes from two AMD patients. Undet,
undetectable.
(G) Relative expression of CXCR1, CXCR2, CXCR4, and CXCR7 mRNA in primary CD14+ monocytes stimulated by IL-17A or IL-17F overnight.
Data are expressed as the means ± SE.expressed the chemokine receptors CXCR2 and CXCR4, we
hypothesized that they might be able to migrate to the macular
regions of the eye. To test whether IL17RC expression could
be found in the macular tissues of AMD patients, we obtained
formalin-fixed, paraffin-embedded (FFPE) archived slides from
26 eyes with either GA (five eyes) or CNV (21 eyes) AMD, as
well as six eyes from age-matched non-AMD controls. We mi-
crodissected the macular tissue into RNA lysis buffer (Ambion)
and extracted total RNA using an RNA extraction kit (Ambion).
We then performed quantitative real-time PCR to detect the
expression of IL17RC mRNA. Interestingly, IL17RC was highly
expressed in the macular tissues of the AMD patients, but notCell Rein those of the non-AMD controls (Figure 4A). Moreover,
immunohistochemistry assays were carried out to detect the
expression of IL-17RC protein in the macular regions of both
AMD and control eyes. As shown in Figures 4B–4E, the immu-
noreactivity against IL-17RC was stronger in the macular
tissues from patients with GA AMD (Figures 4D and S4A)
and CNV AMD (Figures 4E and S4B) than in the macular
tissues from non-AMD controls (Figure 4C) or in the macular
tissues stained with nonspecific antibody (Figure 4B). Thus,
elevated IL17RC expression was found not only in the periph-
eral blood but also in the chorioretinal tissues with AMD
lesions.ports 2, 1151–1158, November 29, 2012 ª2012 The Authors 1155
Figure 4. Expression of IL17RC in the
Macular Tissues of AMD Patients
(A) Relative expression of IL17RC mRNA in
archived microdissectedmacular tissues from five
eyes with GA, 21 eyes with CNV, and six eyes from
non-AMD controls.
(B–E) Immunohistochemistry staining using
nonspecific serum in AMD eyes. Immunohisto-
chemistry staining of IL-17RC protein in non-AMD
control (C), GA (D), and CNV (E) eyes.
Arrows, drusen; asterisk, chorioretinal neo-
vascular fibrous tissue; R, retina; C, choroid. See
also Figures S4A and S4B.DISCUSSION
Twin and sibling designs are broadly used in studies that aim to
dissect the genetic and environmental contributions to various
diseases. Earlier studies using small patient cohorts indicated
a significantly higher concordance rate of AMD in monozygotic
than in dizygotic twins or families, strongly suggesting a genetic
predisposition to AMD (Meyers, 1994, Gottfredsdottir et al.,
1999, Klein et al., 1994, Heiba et al., 1994). In addition,
Hammond et al. (2002) showed that the concordance for AMD
in monozygotic twins was 0.37 compared with 0.19 in dizygotic
twins. Seddon et al. (2005) suggested that genetic factors can
explain 46%–71% of the variation in the overall severity of
AMD; however, they also detected both significant genetic
(0.26–0.71) and unique environmental (0.28–0.64) proportions
of variance for specific macular drusen and retinal pigment
epithelial characteristics. In a later study, Seddon et al. (2011)
suggested that in addition to genetic susceptibility, smoking
and diet associated with epigenetic mechanisms are involved
in the etiology of AMD. We were able to identify three pairs of
twins (one monozygotic and two dizygotic) in our patient cohort
who displayed a significant discordance for end-stage disease,
which gave us a unique opportunity to study the potential epige-
netic differences between them. Our MeDIP-chip analysis iden-
tified differences between AMD twins in 1.5% of the total CpG
sites within 231 gene promoters. This study attempts to address
genome-wide epigenetic regulation in AMD patients. It only
confirms the association between a hypomethylated IL17RC
promoter and the onset of AMD; however, we are in the process
of investigating whether epigenetic regulation of the other 230
genes is also associated with AMD. Our results also suggest
that epigenetic modifications of DNA may be crucial for under-
standing the molecular basis of AMD.
IL-17RC is found highly expressed on the endothelium and
epithelium of the lung, intestine, kidney, prostate, and joint (Ge
and You, 2008). However, it was not clear which types of cells
normally express IL-17RC in the human peripheral blood or
eyes. IL-17RC serves as an essential subunit of the IL-17
receptor complex, which mediates the signal transduction and
proinflammatory activities of IL-17A and IL-17F. Its binding1156 Cell Reports 2, 1151–1158, November 29, 2012 ª2012 The Authorsaffinity, ligand preference, and tissue-
specific distribution differ slightly
between murine and human systems.Recent studies have suggested that high levels of IL-17RC
expression are found in prostate cancer cells, as well as in syno-
viocytes andPBMCs frompatientswith rheumatoid arthritis (Gaf-
fen, 2009). In our study, we found hypomethylated IL17RC
promoters in both GA and CNV AMD patients as compared
with non-AMD controls, which resulted in the increased expres-
sion of its protein in CD14+ monocytes. Moreover, we demon-
strated that IL17A, which was found elevated only in AMD
patients’ serum and macular tissues, induced IL-17RC expres-
sion in primary CD14+ monocyte and human RPE cells, as well
as in THP1 andARPE19 cell lines, suggesting a potentially crucial
role for IL-17A and IL-17RC in the pathogenesis of AMD. Intrigu-
ingly, our results suggested that CD14+IL-17RC+ monocytes ex-
pressed elevated CXCR4 and CXCR2, which serve as the recep-
tors for chemokines such as IL8, CXCL1, CXCL5, and CXCL6.
These chemokines were also highly induced in RPE cells by
both IL-17A and IL-17F. Therefore, Th17-cytokine-induced intra-
ocular inflammation may promote monocyte trafficking into
inflammatory sites within the macular tissues of AMD patients
and eventually cause the pathology of AMD. Therefore, our
results suggest a potentialmechanismbywhichproinflammatory
monocytes could promote AMD pathology.
IL-17-producing Th17 cells are essential for clearing patho-
gens during host defense and for inducing inflammation in auto-
immune disease (Korn et al., 2009). Genetic mutations in genes
involved in IL-17 signaling have been associated with multiple
diseases (Puel et al., 2011, Milner et al., 2008). Our study demon-
strates that epigenetic regulation of IL17RC may also play an
important role in the pathogenesis of AMD, one of the best
genetically characterized complex disorders. More importantly,
promoter DNA methylation patterns and expression of IL17RC
may serve as potential biomarkers for AMD diagnosis and
targets for AMD therapy.
EXPERIMENTAL PROCEDURES
Patients
All protocols were approved by institutional review boards, and written
informed consent for epigenetic and genetic testing and participation was
provided by the patients to the NIH, CEI, or CERA through the Human
Research and Ethics Committee of the Royal Victorian Eye and Ear Hospital.
The Australian Twin Registry (ATR) approved the project. Twin volunteers, both
identical and nonidentical, with or without known eye disease, of either gender,
andR18 years of age, were invited to participate through the ATR. The non-
AMD controls were recruited from the NIH eye clinics and were screened for
AMD. All patients and non-AMD controls were Caucasian. Age and gender
information regarding the subjects is provided in Table S1.
MeDIP-chip and Data Analysis
DNA sample preparation and hybridization to MeDIP-chip were performed ac-
cording to protocols provided by Roche-NimbleGen. Standard data analysis
service was provided by NimbleGen. All raw data and processed bed files
were deposited in the Gene Expression Omnibus with accession number
GSE28033.
Detection of DNA Methylation on Selected Gene Promoters
Genomic DNA was extracted from PBMCs of AMD patients or healthy
controls, as well as from THP1 cells using the DNeasy Blood & Tissue Kit
(QIAGEN) according to the manufacturer’s protocol. Then, 1 mg total genomic
DNA from PBMCs was digested for 6 hr at 37C using the Methyl-Profiler DNA
Methylation Enzyme Kit (SABiosciences) according to the manufacturer’s
instructions. Quantitative real-time PCR was performed with the use of the
ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). The
percentage of methylated DNA was calculated by the difference in threshold
cycle (CT) numbers between samples with total undigested DNA and methyl-
ation-sensitive restriction enzyme-digested DNA.
Cell Culture
PBMCs from healthy controls or AMD patients were cultured in RPMI-1640
medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine,
and 1X penicillin-streptomycin antibiotics (Invitrogen). They were treated with
or without C5A (50 ng/ml), IL-17A (20 ng/ml), or IL-17F (20 ng/ml) overnight, fol-
lowed by FACS sorting for CD3+CD4+ T cells or CD14+ monocytes using
FACSAria II (BD). THP1 cells (ATCC) were cultured in RPMI-1640medium sup-
plemented with 10% FBS, 2 mM L-glutamine, and 1X penicillin-streptomycin
antibiotics (Invitrogen). ARPE-19 cells and primary human RPE cells (ATCC)
were cultured in complete Dulbecco’s modified Eagle’s medium supple-
mentedwith 10%FBS, 2mML-glutamine, and 1X penicillin-streptomycin anti-
biotics (Invitrogen) with or without IL-17A (20 ng/ml), or IL-17F (20 ng/ml)
overnight.
Detection of RNA Expression in THP1 cells, RPE Cells, and CD14+
Monocytes
Total RNA was isolated with the use of a mirVana miRNA isolation kit (Ambion).
Reverse transcriptionofRNAandquantitative real-timePCRwere performedac-
cording to the manufacturer’s protocols, using the primers and probes for 18 s
rRNA (Hs03928990_g1), CXCR1 (Hs00174146_m1), CXCR2 (Hs01011557_m1),
CXCR4 (Hs00607978_s1), CXCR7 (Hs00604567_m1), IL6 (Hs00174131), IL8
(Hs00174103), CXCL1 (Hs00236937), CXCL5 (Hs00607029), and CXCL6
(Hs00605742) from Applied Biosystems. The comparative CT method and 18 s
rRNA was used to normalize the expression.
Detection of IL17A and IL17RC Expression in Human Retinal and
Choroidal Tissues
Archived FFPE ocular sections were first deparaffinized in 100% Xylene ten
times, followed by sequential washes in 100% ethanol, 95% ethanol, 75%
ethanol, and water (ten times in each solution). Total RNA was isolated from
the microdissected macular regions of five eyes with GA, 21 eyes with CNV,
as well as six age-matched eyes without AMD pathology, using mirVana
miRNA kit (Ambion). Reverse transcription of RNA was performed for 12 hr
at 37C, followed by quantitative real-time PCR, using the primers and probes
for 18 s rRNA (Hs03928990_g1), IL17A (Hs00936345), and IL17RC
(Hs00994305_m1) from Applied Biosystems. The comparative CT method
and 18 s rRNA were used to normalize the expression of IL17A and IL17RC.
Statistical Analysis
Statistical analysis was performed usingGraphPad Prism 5.0 software (Graph-
Pad). The Mann-Whitney test was used to compare differences between twoCell Regroups and the significance level was set at p < 0.05. Multivariable logistic
regression analysis was used to detect the difference of the IL17RC promoter
methylation status, adjusted by age, gender, and genotypes of CFH, ARMS2,
or HTRA1, using SAS 9.2. The significance level was set at p < 0.05.
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